Alx oncology announces initiation of investigator-sponsored trial of evorpacept (alx148) in patients with indolent and aggressive non-hodgkin lymphoma

-- phase 1/2 study conducted at the university of texas m.d. anderson cancer center -- phase 1/2 study conducted at the university of texas m.d. anderson cancer center

ALXO Ratings Summary

ALXO Quant Ranking